AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15996609 — intervention group
Group type: COMPARATOR
Intervention: Directional preference‐based exercise alone (n=25)
Number of subjects: 100
Study 15996609 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of heat wrap therapy and exercise (heat+exercise, n=24)
Number of subjects: 100
Study 15996609 — intervention group
Group type: COMPARATOR
Intervention: Control (booklet, n=26)
Number of subjects: 100
Study 14681952 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected diagnosis of colorectal cancer through flexible sigmoidoscopy screening
Number of subjects: 24
Study 14681952 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected diagnosis of colorectal cancer
Number of subjects: 24
Study 14681952 — intervention group
Group type: EXPERIMENTAL
Intervention: Raising awareness of the adenoma-carcinoma sequence
Number of subjects: 24
Study 14681952 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions aimed at reducing distress of screen-detected cancer
Number of subjects: 24
Study 10668692 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-flumazenil (FMZ) PET
Number of subjects: 10
Study 10668692 — intervention group
Group type: EXPERIMENTAL
Intervention: SPM analysis
Number of subjects: 10
Study 10668692 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 10
Study 8694321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily
Number of subjects: 59
Study 8694321 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg daily
Number of subjects: 59
Study 8694321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 1435624 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 30
Study 1435624 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 6705280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 22
Study 6705280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30226022 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent FPS game that rewarded headshots
Number of subjects: 0
Study 30226022 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent shooting game that punished hits to bull's-eye targets with faces
Number of subjects: 0
Study 30226022 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent non-shooting game
Number of subjects: 0
Study 29160486 — intervention group
Group type: EXPERIMENTAL
Intervention: Dramatic Therapeutic Play (DTP)
Number of subjects: 28
Study 29160486 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 26051022 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive-behavioral therapy (CBT) intervention
Number of subjects: 273
Study 26051022 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 273
Study 23515142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg per kg bodyweight intravenously every 4 weeks plus placebo subcutaneously every 2 weeks
Number of subjects: 326
Study 23515142 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg subcutaneously every 2 weeks plus placebo intravenously every 4 weeks
Number of subjects: 326
Study 23515142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 326
Study 23515142 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 326
Study 21333268 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichiasis surgery
Number of subjects: 438
Study 19831164 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.0% arginine toothpaste
Number of subjects: 120
Study 19831164 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 120
Study 19831164 — intervention group
Group type: COMPARATOR
Intervention: Benchmark desensitizing toothpaste
Number of subjects: 120
Study 16618953 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone support intervention (average of 4 calls over 18 months)
Number of subjects: 1413
Study 16618953 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1413
Study 14602286 — intervention group
Group type: EXPERIMENTAL
Intervention: SJM‐AHPJ 21 mm
Number of subjects: 47
Study 14602286 — intervention group
Group type: EXPERIMENTAL
Intervention: SJM‐Regent 21 mm
Number of subjects: 47
Study 14602286 — intervention group
Group type: COMPARATOR
Intervention: CM 21 mm
Number of subjects: 47
Study 14602286 — intervention group
Group type: COMPARATOR
Intervention: CM 23 mm
Number of subjects: 47
Study 14602286 — intervention group
Group type: EXPERIMENTAL
Intervention: SJM‐AHPJ 23 mm
Number of subjects: 47
Study 14602286 — intervention group
Group type: EXPERIMENTAL
Intervention: SJM‐Regent 23 mm
Number of subjects: 47
Study 10350034 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (20-60 mg/day, mean daily dose 48.5 mg)
Number of subjects: 117
Study 10350034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 8606118 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent vaccine composed of Vibrio cholerae CVD 103‐HgR and Salmonella typhi Ty21a
Number of subjects: 330
Study 8606118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 1954640 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% capsaicin cream applied four times daily for four weeks
Number of subjects: 101
Study 1954640 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle cream)
Number of subjects: 101
Study 7318332 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydralazine (16.2‐32.4 mg/2 h) plus saline
Number of subjects: 4
Study 7318332 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine (16.2‐32.4 mg/2 h) plus diclofenac (75 mg/20 ml saline)
Number of subjects: 4
Study 6499689 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-scopolamine
Number of subjects: 46
Study 6499689 — intervention group
Group type: COMPARATOR
Intervention: Meclozine tablets
Number of subjects: 46
Study 30269698 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP‐palliative care version
Number of subjects: 51
Study 30269698 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP‐compassionate palliative care (MCP‐CPC)
Number of subjects: 51
Study 30269698 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 51
Study 26823208 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery (UtA) Doppler screening
Number of subjects: 11667
Study 26823208 — intervention group
Group type: COMPARATOR
Intervention: Non-Doppler group
Number of subjects: 11667
Study 24377410 — intervention group
Group type: EXPERIMENTAL
Intervention: modified cognitive behavioral therapy (m-CBT)
Number of subjects: 43
Study 24377410 — intervention group
Group type: COMPARATOR
Intervention: usual care (UC) therapy
Number of subjects: 43
Study 22656189 — intervention group
Group type: EXPERIMENTAL
Intervention: Han-uvulopalatopharyngoplasty (H‐UPPP)
Number of subjects: 49
Study 22656189 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal PSG)
Number of subjects: 49
Study 19533356 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg by mouth every morning)
Number of subjects: 25
Study 19533356 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized, swallowed fluticasone (440 mcg by mouth twice a day)
Number of subjects: 25
Study 19533356 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole
Number of subjects: 25
Study 19533356 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone
Number of subjects: 25
Study 18476433 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongdatang serial recipe (TDT)
Number of subjects: 100
Study 18476433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15839957 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine-carboplatin
Number of subjects: 356
Study 15839957 — intervention group
Group type: COMPARATOR
Intervention: carboplatin
Number of subjects: 356
Study 12599218 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy for Stage II breast carcinoma
Number of subjects: 0
Study 10228115 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Dyspnea Rating (TDR)
Number of subjects: 44
Study 10228115 — intervention group
Group type: COMPARATOR
Intervention: Target Heart Rate (THR)
Number of subjects: 44
Study 8712160 — intervention group
Group type: EXPERIMENTAL
Intervention: HGSHS: A and SHSS:C
Number of subjects: 280
Study 8712160 — intervention group
Group type: EXPERIMENTAL
Intervention: CIS and SHSS:C
Number of subjects: 280
Study 8712160 — intervention group
Group type: EXPERIMENTAL
Intervention: HGSHS: A and SHCS:A
Number of subjects: 280
Study 8712160 — intervention group
Group type: EXPERIMENTAL
Intervention: CIS and SHCS:A
Number of subjects: 280
Study 8712160 — intervention group
Group type: COMPARATOR
Intervention: SHSS:C alone
Number of subjects: 280
Study 2064139 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methacholine
Number of subjects: 0
Study 2064139 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol
Number of subjects: 0
Study 2064139 — intervention group
Group type: COMPARATOR
Intervention: Physiologic variables (peak inspiratory flow, tidal volume/FVC, frequency of respiration, peak inspiratory mouth pressures)
Number of subjects: 0
Study 2064139 — intervention group
Group type: COMPARATOR
Intervention: Borg rating of breathlessness
Number of subjects: 0
Study 2064139 — intervention group
Group type: COMPARATOR
Intervention: Test-retest reliability
Number of subjects: 0
Study 2064139 — intervention group
Group type: COMPARATOR
Intervention: Work intensity (watts)
Number of subjects: 0
Study 7109137 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized method for calculating gentamicin dosage
Number of subjects: 96
Study 7109137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dettli method
Number of subjects: 96
Study 7109137 — intervention group
Group type: EXPERIMENTAL
Intervention: Chan method
Number of subjects: 96
Study 7109137 — intervention group
Group type: COMPARATOR
Intervention: Sarubbi‐Hull method
Number of subjects: 96
Study 7109137 — intervention group
Group type: COMPARATOR
Intervention: Rule of eights method
Number of subjects: 96
Study 31238081 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy beverage (200 ml consumed once a day for 15 days)
Number of subjects: 0
Study 31238081 — intervention group
Group type: COMPARATOR
Intervention: Bovine milk (200 ml consumed once a day for 15 days)
Number of subjects: 0
Study 31238081 — intervention group
Group type: EXPERIMENTAL
Intervention: Both beverages
Number of subjects: 0
Study 30307902 — intervention group
Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 154
Study 30307902 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG + Infliximab
Number of subjects: 154
Study 26875114 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (20mg p.o.)
Number of subjects: 36
Study 26875114 — intervention group
Group type: COMPARATOR
Intervention: Ergotamine (3mg p.o.)
Number of subjects: 36
Study 25440374 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenzhu Tiaopi granule (SZTP) plus lifestyle intervention
Number of subjects: 514
Study 25440374 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention (control group)
Number of subjects: 514
Study 21719715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined clinic (CC)
Number of subjects: 139
Study 21719715 — intervention group
Group type: COMPARATOR
Intervention: Standard care (MC)
Number of subjects: 139
Study 20649426 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (400 mg, twice daily)
Number of subjects: 76
Study 20649426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 18041171 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazax (oral vaccine)
Number of subjects: 3
Study 18041171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 16335327 — intervention group
Group type: EXPERIMENTAL
Intervention: MWT1 sleep latency under partial sleep deprivation
Number of subjects: 20
Study 16335327 — intervention group
Group type: EXPERIMENTAL
Intervention: MWT1 sleep latency under partial sleep deprivation and alcohol condition
Number of subjects: 20
Study 16335327 — intervention group
Group type: EXPERIMENTAL
Intervention: MWT1 sleep latency in the partial sleep deprivation plus alcohol condition
Number of subjects: 20
Study 12538215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine microcapsules (0.3125% to 5.0%)
Number of subjects: 0
Study 12538215 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine microcapsules (2.5%) with dexamethasone
Number of subjects: 0
Study 12538215 — intervention group
Group type: COMPARATOR
Intervention: 0.25% aqueous bupivacaine
Number of subjects: 0
Study 9917081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol titrated at 10 days to achieve 200 mg/day
Number of subjects: 465
Study 9917081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol titrated at 4 days to achieve 200 mg/day
Number of subjects: 465
Study 9917081 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol titrated at 1 day to achieve 200 mg/day
Number of subjects: 465
Study 9917081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study 7494615 — intervention group
Group type: EXPERIMENTAL
Intervention: F60S
Number of subjects: 9
Study 7494615 — intervention group
Group type: EXPERIMENTAL
Intervention: SPAN
Number of subjects: 9
Study 7494615 — intervention group
Group type: EXPERIMENTAL
Intervention: PAN
Number of subjects: 9
Study 1962781 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy and thoracic irradiation
Number of subjects: 0
Study 7282733 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol metaproterenol (3 puffs)
Number of subjects: 18
Study 7282733 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aminophylline (0.4 to 0.6 g)
Number of subjects: 18
Study 7282733 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both (aminophylline and metaproterenol)
Number of subjects: 18
Study 7282733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31121136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 14335
Study 31121136 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal delivery
Number of subjects: 14335
Study 31121136 — intervention group
Group type: COMPARATOR
Intervention: Cesarean delivery
Number of subjects: 14335
Study 23242955 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 310
Study 21706943 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) based ART
Number of subjects: 134
Study 21706943 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) based ART
Number of subjects: 134
Study 21706943 — intervention group
Group type: COMPARATOR
Intervention: NVP and EFV (combined)
Number of subjects: 134
Study 21706943 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV co-infection
Number of subjects: 134
Study 19422982 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 607
Study 19422982 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 607
Study 16397159 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisite physical activity intervention program developed from formative research
Number of subjects: 64
Study 16397159 — intervention group
Group type: EXPERIMENTAL
Intervention: Formative research conducted through interviews with principals and physical education department heads
Number of subjects: 64
Study 15576957 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty
Number of subjects: 0
Study 15576957 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 0
Study 15576957 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 11089714 — intervention group
Group type: EXPERIMENTAL
Intervention: EBM course, taught 2 hours per week for 7 consecutive weeks by senior faculty and chief residents
Number of subjects: 55
Study 11089714 — intervention group
Group type: COMPARATOR
Intervention: Control group after it crossed over to receive the intervention
Number of subjects: 55
Study 9165972 — intervention group
Group type: EXPERIMENTAL
Intervention: Delivery of oxygen at 21.min‐1 via nasal cannulae
Number of subjects: 30
Study 9165972 — intervention group
Group type: COMPARATOR
Intervention: Oxygen directed from under the surgical drapes
Number of subjects: 30
Study 8239103 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg methylprednisolone acetate suspension
Number of subjects: 70
Study 8239103 — intervention group
Group type: COMPARATOR
Intervention: IM saline placebo
Number of subjects: 70
Study 3701584 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed slide images
Number of subjects: 39
Study 3701584 — intervention group
Group type: COMPARATOR
Intervention: Figure-ground composite images
Number of subjects: 39
Study 30094809 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Care Transitions Intervention (CTI) delivered by community paramedics
Number of subjects: 422
Study 25972203 — intervention group
Group type: EXPERIMENTAL
Intervention: CrossFit Teens™ resistance training programme (60 min, twice per week for 8 weeks)
Number of subjects: 96
Study 25939638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.1 mg/kg body weight) and nitrous oxide‐oxygen sedation
Number of subjects: 30
Study 25939638 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (0.2 mg/kg body weight) and nitrous oxide‐oxygen sedation
Number of subjects: 30
Study 23473703 — intervention group
Group type: EXPERIMENTAL
Intervention: Driven gait orthosis (DGO)
Number of subjects: 62
Study 23473703 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-based locomotor training with manual assistance (TM)
Number of subjects: 62
Study 23473703 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TS)
Number of subjects: 62
Study 23473703 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground locomotor training with electrical stimulation (OG)
Number of subjects: 62
Study 21778716 — intervention group
Group type: EXPERIMENTAL
Intervention: M-EDTA
Number of subjects: 50
Study 21778716 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 50
Study 19433697 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized acupuncture
Number of subjects: 638
Study 19433697 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized acupuncture
Number of subjects: 638
Study 19433697 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated acupuncture
Number of subjects: 638
Study 19433697 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 638
Study 19433697 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized, standardized, or simulated acupuncture
Number of subjects: 638
Study 16421476 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50-100 mg
Number of subjects: 14
Study 16421476 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5-25 mg
Number of subjects: 14
Study 16421476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15351409 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile bearing (group B)
Number of subjects: 40
Study 15351409 — intervention group
Group type: COMPARATOR
Intervention: Fixed bearing (group A)
Number of subjects: 40
Study 11545670 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care clinic (n = 59)
Number of subjects: 120
Study 11545670 — intervention group
Group type: COMPARATOR
Intervention: General medicine clinic (n = 61)
Number of subjects: 120
Study 9259053 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (nonspecific competitive adenosine receptor antagonist)
Number of subjects: 22
Study 9259053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7864610 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose yogurt
Number of subjects: 10
Study 7864610 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% and 10% sucrose yogurt
Number of subjects: 10
Study 7864610 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake days (yogurt consumption)
Number of subjects: 10
Study 7864610 — intervention group
Group type: COMPARATOR
Intervention: Sensory evaluation days (no yogurt consumption)
Number of subjects: 10
Study 2573572 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (250-micrograms bolus and 250-micrograms per hr infusion, with repeat bolus and doubling of the infusion if bleeding was not controlled)
Number of subjects: 102
Study 2573572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 2573572 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 102
Study 1026339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside
Number of subjects: 0
Study 1026339 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0
Study 1026339 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 0
Study 1026339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle-sensitive schedule with cytosine arabinoside
Number of subjects: 0
Study 1026339 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive-chemotherapy schedule
Number of subjects: 0
Study 1026339 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial LI greater than 60% reduction in circulating leukemia cells
Number of subjects: 0
Study 1026339 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial kinetic measurements
Number of subjects: 0
Study 31672481 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical blood flow restriction (pBFR) during boat‐ and indoor‐rowing training (n=16; 4 female, 12 male)
Number of subjects: 31
Study 31672481 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) without pBFR (n=15; 4 female, 11 male)
Number of subjects: 31
Study 31672481 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical blood flow restriction (pBFR)
Number of subjects: 31
Study 31370981 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (VAR)
Number of subjects: 137
Study 31370981 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 137